You just read:

U.S. FDA Approves Supplemental New Drug Application (sNDA) for ERLEADA® (apalutamide) for the Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Sep 17, 2019, 20:29 ET